2007
Cost-Effectiveness of Switching to Exemestane after 2 to 3 Years of Therapy with Tamoxifen in Postmenopausal Women with Early-Stage Breast Cancer
Thompson D, Taylor DC, Montoya EL, Winer EP, Jones SE, Weinstein MC. Cost-Effectiveness of Switching to Exemestane after 2 to 3 Years of Therapy with Tamoxifen in Postmenopausal Women with Early-Stage Breast Cancer. Value In Health 2007, 10: 367-376. PMID: 17888101, DOI: 10.1111/j.1524-4733.2007.00190.x.Peer-Reviewed Original ResearchMeSH KeywordsAgedAndrostadienesAntineoplastic ProtocolsAromatase InhibitorsBreast NeoplasmsCost-Benefit AnalysisDrug Administration ScheduleFemaleForecastingHumansMarkov ChainsMiddle AgedNeoplasm Recurrence, LocalPostmenopauseQuality-Adjusted Life YearsSEER ProgramSelective Estrogen Receptor ModulatorsTamoxifenConceptsIntergroup Exemestane StudyDisease-free survivalDisease-related eventsTreatment strategiesEarly-stage breast cancer patientsEarly-stage breast cancerProlongs disease-free survivalCost-effective treatment strategyIncremental cost-effectiveness ratioYears of tamoxifenYears of therapyBreast cancer patientsSEER-Medicare dataBreast cancer statusLifetime medical care costsMedical care costsCost-effectiveness ratioTamoxifen therapyPostmenopausal womenRecurrence rateCancer careCancer patientsPatient transitionsAromatase inhibitorsBreast cancer
1999
Is axillary lymph node dissection indicated for early-stage breast cancer? A decision analysis.
Parmigiani G, Berry D, Winer E, Tebaldi C, Iglehart J, Prosnitz L. Is axillary lymph node dissection indicated for early-stage breast cancer? A decision analysis. Journal Of Clinical Oncology 1999, 17: 1465-73. PMID: 10334532, DOI: 10.1200/jco.1999.17.5.1465.Peer-Reviewed Original ResearchConceptsAxillary lymph node dissectionBenefits of ALNDLymph node dissectionQuality of lifeAdjuvant chemotherapyAdjuvant therapyNode dissectionBreast cancerLeukemia Group B StudyEarly-stage breast cancerRoutine useAxillary radiation therapyER-negative womenER-positive womenAdjuvant systemic therapySmall primary tumorsBreast-conserving therapyBreast cancer patientsEstrogen receptor statusNegative axillaOxford OverviewAdjuvant treatmentChemotherapy combinationsSurvival benefitSystemic therapy
1998
Testing for the BRCA1 and BRCA2 Breast-Ovarian Cancer Susceptibility Genes
Tengs TO, Winer EP, Paddock S, Aguilar-Chavez O, Berry DA. Testing for the BRCA1 and BRCA2 Breast-Ovarian Cancer Susceptibility Genes. Medical Decision Making 1998, 18: 365-375. PMID: 10372578, DOI: 10.1177/0272989x9801800402.Peer-Reviewed Original ResearchAdultAgedBreast NeoplasmsDecision Support TechniquesFemaleGenes, BRCA1Genes, Tumor SuppressorGenetic Predisposition to DiseaseGenetic TestingHumansIncidenceMarkov ChainsMastectomyMiddle AgedOvarian NeoplasmsOvariectomyPredictive Value of TestsQuality-Adjusted Life YearsRisk AssessmentSurvival AnalysisUnited States